Vosoritide

Brand names: Voxzogo 0.4Mg, Voxzogo 0.56Mg, Voxzogo 1.2Mg · Active ingredient: Vosoritide

In short: VOXZOGO is indicated to increase linear growth in pediatric patients with achondroplasia with open epiphyses. This indication is approved under accelerated approval based on an improvement in annualized growth velocity .

Forms & strengthsFor Injection: 0.4 mg, 0.56 mg, or 1.2 mg of vosoritide as a white to yellow lyophilized powder in a single-dose vial for reconstitution.
LabelBioMarin Pharmaceutical Inc.
Label updatedNov 26, 2025

What is Vosoritide used for?

VOXZOGO is indicated to increase linear growth in pediatric patients with achondroplasia with open epiphyses. This indication is approved under accelerated approval based on an improvement in annualized growth velocity . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

Vosoritide dosage

To reduce the risk of low blood pressure and its associated signs and symptoms, instruct the caregiver and patient that the patient should :

Have adequate food intake prior to VOXZOGO administration.

Drink approximately 240 to 300 mL of fluid in the hour prior to VOXZOGO administration.

The recommended dosage of VOXZOGO is based on the patient's actual body weight . VOXZOGO is administered by subcutaneous injection once daily .

Inject VOXZOGO at approximately the same time each day, if possible. The volume of VOXZOGO to be administered (injection volume) is based on the patient's actual body weight and the concentration of reconstituted VOXZOGO (0.8 mg/mL or 2 mg/mL) . VOXZOGO must be reconstituted prior to use .

Actual Body WeightIntermediate body weights that fall within these weight bands should be rounded to the nearest whole number. | Dose | Injection Volume | Vial Strength for ReconstitutionThe concentration of vosoritide in reconstituted 0.4 mg vial and 0.56 mg vial is 0.8 mg/mL. The concentration of vosoritide in reconstituted 1.2 mg vial is 2 mg/mL.

3 kg | 0.096 mg | 0.12 mL | 0.4 mg

4 kg | 0.12 mg | 0.15 mL | 0.4 mg

5 kg | 0.16 mg | 0.2 mL | 0.4 mg

6 to 7 kg | 0.2 mg | 0.25 mL | 0.4 mg

8 to 11 kg | 0.24 mg | 0.3 mL | 0.4 mg

12 to 16 kg | 0.28 mg | 0.35 mL | 0.56 mg

17 to 21 kg | 0.32 mg | 0.4 mL | 0.56 mg

22 to 32 kg | 0.4 mg | 0.5 mL | 0.56 mg

33 to 43 kg | 0.5 mg | 0.25 mL | 1.2 mg

44 to 59 kg | 0.6 mg | 0.3 mL | 1.2 mg

60 to 89 kg | 0.7 mg | 0.35 mL | 1.2 mg

≥ 90 kg | 0.8 mg | 0.4 mL | 1.2 mg

Missed dose

If a dose of VOXZOGO is missed, it can be administered within 12 hours of the scheduled time of administration. Beyond 12 hours, skip the missed dose and administer the next daily dose according to the usual dosing schedule.

Monitor and assess patient body weight, growth, and physical development regularly every 3 to 6 months. Adjust the dosage according to the patient's actual body weight .

Permanently discontinue VOXZOGO upon confirmation of no further growth potential, indicated by closure of epiphyses.

Reconstitute VOXZOGO before administration using the provided diluent syringe containing Sterile Water for Injection, USP .

Caregivers may inject VOXZOGO subcutaneously after proper training by a healthcare professional on the preparation and administration of VOXZOGO .

Reconstitution Instructions

Select the correct VOXZOGO vial strength (co-packaged with prefilled syringe with Sterile Water for Injection diluent) based on the patient's actual body weight .

Remove VOXZOGO vial and prefilled diluent syringe from the refrigerator and allow the vial and prefilled diluent syringe to reach room temperature before reconstituting VOXZOGO.

Attach the diluent needle provided with ancillary supplies to the diluent prefilled syringe. …

How to take Vosoritide — instructions & advice from the label

Advise the patient and caregiver to read the FDA-approved patient labeling (Patient Information and Instructions for Use).

Preparation and Administration

Instruct caregivers on proper preparation and administration of VOXZOGO. Ensure caregivers have demonstrated the ability to perform a subcutaneous injection .

Instruct caregivers in the technique of proper syringe and needle disposal, and advise them not to reuse these items. Instruct caregivers to dispose needles and syringes in a puncture-resistant container.

Risk of Low Blood Pressure

Inform caregivers and patients that VOXZOGO may lower blood pressure after administration. Instruct caregivers and patients that prior to VOXZOGO administration, the patient should have adequate food intake and within the hour prior to administration, the patient should drink approximately 8-10 ounces (240-300 mL) of fluid .

Warnings & precautions

Do not take this medicine if: None

Transient decreases in blood pressure were observed in clinical studies of VOXZOGO. Subjects with significant cardiac or vascular disease and patients on anti-hypertensive medicinal products were excluded from participation in VOXZOGO clinical trials. To reduce the risk of a decrease in blood pressure and associated symptoms (dizziness, fatigue and/or nausea), instruct patients to be well hydrated and have adequate food intake prior to administration of VOXZOGO .

Vosoritide side effects

The following clinically significant adverse reactions are described elsewhere in the labeling:

Risk of Low Blood Pressure

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Pediatric Patients 5 Years of Age and Older

VOXZOGO was studied in a 52-week, randomized, double-blind, placebo-controlled trial in 121 subjects with achondroplasia (Study 1) .

The subjects' ages ranged from 5.1 to 14.9 years with a mean of 8.7 years. Sixty four (53%) subjects were male and 57 (47%) were female. Overall, 86 (71%) subjects were White, 23 (19%) were Asian, 5 (4%) were Black or African American, and 7 (6%) were classified as "multiple" race. The demographic and baseline characteristics were balanced between treatment groups. The subjects received either VOXZOGO 15 mcg/kg, or placebo administered subcutaneously once daily.

Table 3 shows adverse reactions that occurred in ≥5% of patients treated with VOXZOGO and at a percentage greater than placebo.

Adverse Reaction | Placebo(N=61)n (%) | VOXZOGO(N=60)n (%)

Abbreviations: N, total number of subjects in the treatment arm; n, number of subjects with the adverse reaction; %, percent of subjects with the adverse reaction. …

About this medicine

VOXZOGO contains vosoritide, a human C type natriuretic peptide (CNP) analog. Vosoritide is a 39 amino acid peptide. Its amino acid sequence includes the 37 C terminal amino acids of the human CNP53 sequence plus Pro Gly on the N terminus to convey resistance to neutral endopeptidase (NEP) degradation. Vosoritide is manufactured from Escherichia coli using recombinant DNA technology. Vosoritide has a chemical formula of C176H290N56O51S3 with a molecular weight of 4.1 kDa.

Vosoritide has the structural formula shown in Figure 1.

Figure 1

VOXZOGO (vosoritide) for injection, is a sterile, preservative-free white-to-yellow lyophilized powder, for subcutaneous administration after reconstitution with Sterile Water for Injection, USP.

VOXZOGO is provided as a single-dose vial containing 0.4 mg, 0.56 mg, or 1.2 mg of vosoritide per vial. A pre-filled syringe containing Sterile Water for Injection, USP for use as a diluent is also provided. The contents of each single dose vial are summarized by strength in Table 4. The product contains no preservative. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 228e8560-04a4-4bb1-a81f-29531a9e4d27. Read the full official label on DailyMed.